
Stereotaxis Announces First GenesisX Robotic System Order
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.
'We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital,' said David Fischel, Stereotaxis Chairman and CEO. 'Establishing the first GenesisX robotic lab is a critical milestone for us as we advance towards full commercial launch. We look forward to demonstrating the performance and reliability of GenesisX in the demanding clinical environment. GenesisX promises to transform the accessibility of Robotic Magnetic Navigation and is central to our mission of driving broad robotic adoption throughout endovascular surgery.'
GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for healthcare providers. GenesisX utilizes smaller magnets and incorporates magnetic shielding into its structure in place of the shielding otherwise installed in the walls of the operating room. It requires no structural anchoring through the floor and operates using standard 120/230V power outlets. A single fiber is routed from each robot to the system cabinet, which is 80% smaller than previous cabinets and can fit under a table in the operating room. GenesisX is smaller and lighter than any previous generation system, while maintaining the highest standards in speed, responsiveness, and efficient workflow.
GenesisX obtained CE Mark in Europe in 2024 and has been submitted to the FDA for 510(k) clearance in the United States. During 2025, Stereotaxis plans to gain regulatory approvals in Europe and the US for a portfolio of compatible EP and vascular catheters, demonstrate real-world use of GenesisX, enhance compatibility of GenesisX with various x-rays, and prepare supply chain, manufacturing, installation and commercial processes for a full launch.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute 'forward-looking' statements, usually containing the words 'believe', 'estimate', 'project', 'expect' or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
David L. Fischel
Kimberly Peery
Chief Financial Officer
314-678-6100
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
2 Growth Stocks to Stash and 1 to Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Yahoo
26 minutes ago
- Yahoo
Global Market's Top 3 Stocks That Could Be Undervalued In June 2025
As global markets navigate a mixed economic landscape, with U.S. stocks climbing for the second consecutive week and European indices buoyed by easing monetary policies, investors are keenly observing the potential impacts of trade tensions and labor market shifts. Amid these developments, identifying undervalued stocks can be particularly appealing as they may offer opportunities for growth when market conditions are uncertain. Name Current Price Fair Value (Est) Discount (Est) Wanguo Gold Group (SEHK:3939) HK$30.70 HK$61.36 50% Sparebank 68° Nord (OB:SB68) NOK179.38 NOK357.46 49.8% Sahara International Petrochemical (SASE:2310) SAR18.98 SAR37.71 49.7% PixArt Imaging (TPEX:3227) NT$220.00 NT$436.00 49.5% Montana Aerospace (SWX:AERO) CHF19.50 CHF38.68 49.6% Good Will Instrument (TWSE:2423) NT$44.30 NT$87.18 49.2% Exsitec Holding (OM:EXS) SEK128.50 SEK254.56 49.5% doValue (BIT:DOV) €2.258 €4.45 49.3% Airbus (ENXTPA:AIR) €163.92 €325.62 49.7% ABO Energy GmbH KGaA (XTRA:AB9) €36.70 €72.88 49.6% Click here to see the full list of 495 stocks from our Undervalued Global Stocks Based On Cash Flows screener. Let's review some notable picks from our screened stocks. Overview: SILICON2 Co., Ltd. is involved in the global distribution of cosmetics products and has a market cap of ₩3.40 billion. Operations: The company generates revenue primarily through its wholesale miscellaneous segment, which amounts to ₩787.27 million. Estimated Discount To Fair Value: 41.1% SILICON2 is trading at ₩61,800, significantly below its estimated fair value of ₩104,926.19, suggesting it may be undervalued based on cash flows. Despite high volatility in recent months, the company reported strong earnings growth of 134.2% over the past year and forecasts revenue and earnings growth above 20% annually. Recent results showed net income rising to KRW 38,785 million from KRW 25,535.55 million a year ago with improved earnings per share figures. The analysis detailed in our SILICON2 growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of SILICON2. Overview: Qingdao Baheal Medical INC. is involved in the research, development, production, and sale of pharmaceutical products with a market cap of approximately CN¥11.10 billion. Operations: The company's revenue is derived from its activities in research, development, production, and sale of pharmaceutical products. Estimated Discount To Fair Value: 15.2% Qingdao Baheal Medical is trading at CNY 23.29, below its estimated fair value of CNY 27.46, indicating potential undervaluation based on cash flows. Despite a slight decline in recent sales and net income compared to the previous year, earnings are projected to grow significantly over the next three years. The company recently affirmed a dividend distribution plan for 2024, reflecting stable shareholder returns amidst moderate revenue growth expectations above the Chinese market average. Our growth report here indicates Qingdao Baheal Medical may be poised for an improving outlook. Click to explore a detailed breakdown of our findings in Qingdao Baheal Medical's balance sheet health report. Overview: Fositek Corp. operates in the manufacture and wholesale of electronic materials and components, with a market cap of NT$47.58 billion. Operations: The company's revenue primarily comes from its Electronic Components & Parts segment, generating NT$8.73 billion. Estimated Discount To Fair Value: 47% Fositek is trading at NT$762, significantly below its estimated fair value of NT$1,437.14, highlighting potential undervaluation based on cash flows. The company reported strong first-quarter earnings with net income rising to TWD 356.5 million from TWD 223.95 million year-over-year. Earnings are projected to grow substantially at 33.9% annually over the next three years, outpacing Taiwan's market average growth rates despite recent share price volatility and changes in company bylaws. The growth report we've compiled suggests that Fositek's future prospects could be on the up. Delve into the full analysis health report here for a deeper understanding of Fositek. Investigate our full lineup of 495 Undervalued Global Stocks Based On Cash Flows right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A257720 SZSE:301015 and TWSE:6805. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Basecamp Research Announces Breakthrough Discovery of Over One Million New Species, Yielding Enormous New Database Purpose-Built for Generative Foundation Models in Biology
Head to Head Comparison 10X Tree of Life Basecamp Research_Cameroon Basecamp Research_CostaRica Uncharted Diversity Kmer Umap DNA Basecamp Research_Malta Company's multi-year biodiscovery programme, driven by strategic economic partnerships across 26 countries, has resulted in BaseDataTM the largest and fastest growing database of new biological protein sequences - 9.8 billion - ever built New species data gives scientists new potential therapeutic solutions to areas including antimicrobial resistance, gene editing, and environmental sustainability Scientific preprint demonstrates how BaseData breaks through biology's data wall and now exceeds the size, growth and diversity of public datasets that serve as the foundations for AI applications in the life sciences industry LONDON and CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Basecamp Research, an AI company dedicated to using nature to solve the most pressing challenges in the life sciences, today announced the discovery of over 1 million new species as part of BaseDataTM, the world's largest biological protein sequence database, and the first to be purpose-built to power the next era of generative biology. 'The rise of generative biology – using AI foundation models to design, generate, and annotate proteins, pathways and therapeutics – creates unprecedented demand for large, diverse biological sequence databases,' said Glen Gowers, Ph.D., CEO and Co-Founder of Basecamp Research. 'The million plus new species we've identified to date gives us an unrivaled understanding of how life on Earth has evolved over billions of years. We believe it will help the life sciences sector overcome today's critical data bottleneck and build a truly generative biology ecosystem with applications across nearly every area of human and planetary health.' Today, research relies heavily on public, open access biological sequence databases. Designed originally as academic collaboration tools, these databases are accessed over 100 million times per day and are the source of over 50% of all life science patents. This usage has grown by 10x in the last decade and continues to accelerate thanks in large part to the increasing use of data-hungry AI models in biopharma research. However, compared to all life on Earth, these databases are incomplete, riddled with redundancies, and highly-biased – 70% of all sequence data comes from just 10 species. Furthermore, the information in these databases is growing slowly, and companies using these databases for commercial purposes face increasing scrutiny on various legal fronts. This lack of growth and diversity holds back model performance and is a fundamental problem that slows research advancements in the life sciences: the data wall. Basecamp Research has broken through this data wall by pioneering an economic partnership-based model that incentivises the collection of samples across the planet's most extreme and biodiverse environments, working with 125+ communities in 26 countries. In a milestone disclosure, the company is unveiling the results of its biodiscovery initiative — BaseData has identified 9.8 billion new protein sequences. Once redundant sequences are removed, BaseData is currently over 10x bigger than all public databases combined. It continues to grow rapidly, offering a fundamentally new understanding of life on Earth. 'Biological foundation models are the key to continued progress in the life sciences, but their growth is slowing and performance is suffering,' said Oliver Vince, Ph.D., Co-Founder of Basecamp Research. 'It's this data wall that discourages life science teams in building and using huge biological foundation models. At Basecamp, we've demonstrated a new, scalable economic framework for expanding our knowledge of life on Earth and we show it is possible to overcome the data wall that's limiting progress for others in bioAI. Training our own foundation models on this data is enabling collaborations across the life sciences sector to help solve pressing challenges in drug discovery.' Basecamp Research scientists have uncovered more than one million new microbial species to date in some of the planet's most remote and extreme environments, expanding the view of the tree of life by over 10 times. The previously hidden biological insights in this data, combined with foundational AI models, will help shape everything from environmental sustainability and repair to therapeutics development. Examples of such newly discovered species include: On a World War II shipwreck, a new species of Burkholderia, a type of bacteria known for its ability to remove heavy metals from the environment. This could help improve pollution control and deepen our understanding of how bacteria resist antibiotics. In acidic hot springs near an active volcano, a new member of the Sulfolobaceae family that thrives in searing temperatures. Its specialized proteins, stress-response systems and stability near boiling point could help develop new ways to deliver medicine or preserve biological materials under harsh conditions. In Antarctic soil, a new species of Candidatus Eremiobacterota, a bacterium that survives by drawing nourishment from the air, generating its own water using hydrogen as an energy source — a finding that could inform novel gas-based drug delivery systems or therapeutic approaches. Basecamp Research is sharing further details in a pre-print paper and plans to offer early access to its unique data to life sciences researchers who express interest via its website to help them further their research. About Basecamp ResearchBasecamp Research is solving the most pressing challenges in the life sciences by exploring Beyond Known BiologyTM. We build foundational AI models on top of the world's largest, ethically-sourced database of biological information to give AI the most complete understanding of biology ever. This allows us to design more complex biological systems with performance improving dramatically as AI sees more diversity and context. Basecamp Research collaborates with biopharma companies and academic research institutions to design novel protein sequences and biological systems that can transform therapeutic research and development. Our team of explorers, scientists and policy experts proudly work with more than 100 biodiversity partners across the globe, allowing us to deliver breakthroughs that can have a profound impact on healthcare and the lives of patients. Fast Company named Basecamp Research one of biotech's top 10 Most Innovative Companies in 2025. For more information, visit BaseDataTM and Beyond Known BiologyTM are brand names and technologies of Basecamp Research. Media Contact:Adam SilversteinSCIENT PRadam@ Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data